Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This online program is recorded content from the live session at Rural Health Clinical Congress Fall 2024 and is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi. This activity is supported by an independent medical education grant from Eisai, Inc.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.25 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, and pharmacists who care for patients from rural and underserved communities.

Program Overview

Alzheimer’s disease is often not diagnosed until later in the disease process, especially in rural and underserved communities where barriers such as limited access to specialists can impede care. Primary care clinicians who practice in these settings play an outsized role in management that will likely only increase as the population ages. Therefore, their influence on care and patient outcomes is tremendous. In this CME/CE activity, expert faculty will discuss best practices for screening and treatment of Alzheimer’s disease in the primary care setting, including how to differentiate it from normal signs of aging. Practical strategies to improve collaborative management of the condition in conjunction with specialists will also be discussed. 

This enduring activity is a recorded session from Rural Health Clinical Congress Fall 2024 that took place on November 23, 2024.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Differentiate signs and symptoms of early Alzheimer’s disease from those associated with normal aging 
• Incorporate evidence-based tools and strategies for screening and assessment of Alzheimer’s disease into routine clinical practice
• Evaluate the latest clinical data on efficacy and safety of approved and emerging disease-modifying therapies
• Utilize effective methods to improve access to care and collaborative management of patients with Alzheimer’s disease who reside in rural and underserved communities 

Faculty

Gary W. Small, MD
Chair of Psychiatry, Hackensack University Medical Center  
Vice President, Behavioral Health Physician-in-Chief  
H. Hovnanian Family Foundation Chair  
Hackensack Meridian Health
Professor and Chair of Psychiatry & Behavioral Health  
Hackensack Meridian School of Medicine
Hackensack, NJ  

Cody A. Chastain, MD, MEHP 
Associate Professor of Medicine 
Vanderbilt University Medical Center 
Nashville, TN

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. 
(Universal Activity Number – JA4008332-0000-25-005-H01-P) 
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Gary W. Small, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Acadia Pharmaceutics, Inc., Allergan, Inc. (now AbbVie, Inc.), Biogen, Inc., Cogensus AI, Inc., Electro Cellular Healthcare Solutions, LLC, Eli Lilly and Company, Handok, Inc., Lundbeck, Inc., McCormick Science Institute, Merry Life Biomedical Company, Ltd., Otsuka America Pharmaceutical, Inc. (previously Avanir Pharmaceuticals, Inc.), R. Hoffman-La Roche, Ltd., and Theravalues.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets:
All devices

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.